Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of the Efficacy and Safety of Nebivolol in Younger Patients (18 - 54 Years) Who Have Stage 1 or 2 Essential Hypertension.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Oct 2013
Price :
$35
*
At a glance
- Drugs Nebivolol (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 01 Sep 2013 Primary endpoint 'Seated-blood-pressure' has been met according to results published in the Journal of Clinical Hypertension (Greenwich).
- 01 Sep 2013 Primary endpoint 'Diastolic-blood-pressure' has been met according to results published in the Journal of Clinical Hypertension (Greenwich).
- 01 Sep 2013 Results published in the Journal of Clinical Hypertension (Greenwich).